AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03791203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction (MACR)
Description: This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
Study NCT01874106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Therapy
Description: The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
Study NCT01874106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
Study NCT03811106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuromuscularElectricalStimulation+ConventionalPhysiotherapy
Description: Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
Study NCT03811106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy and rehabilitation
Description: Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
Study NCT01683240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cholangioscopy (Frimberger)
Description: cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
Study NCT02273297 — intervention group
Intervention type: OTHER
Intervention: Maternal factors
Study NCT01710917 — intervention group
Intervention type: DRUG
Intervention: Targinact® (oxycodon/naloxon)
Study NCT01589952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegalyted interferon, Entecavir
Description: Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
Study NCT00692406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Study NCT02702700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, liposomal
Description: Lipoplatin IV 200 mg/m2
Study NCT02702700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Visudyne® IV 3 mg/m2
Study NCT02702700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry
Description: Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
Study NCT00543660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
Study NCT01762423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Device (IVIVI SofPulse)
Study NCT01762423 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study NCT03324711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Antillanisée Mini Mental State Examination (MMSEa)
Description: Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture.
Study NCT02534532 — intervention group
Intervention type: OTHER
Intervention: AF screening
Description: Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
Study NCT04060225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Starbuck's brand blonde roast coffee, 20 ounces
Study NCT04654247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality audit and feedback
Description: Endoscopists received quality report generated by Endo.Adm.
Study NCT04654247 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: None feedback.
Study NCT01377558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training intervention
Description: The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week
Study NCT01377558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength endurance training intervention
Description: The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week
Study NCT01377558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined aerobic endurance and strength endurance training
Description: week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week
Study NCT02235701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 170 mg/m2 aldoxorubicin
Description: administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study NCT01864915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule
Description: Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
Study NCT03546426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
Study NCT03546426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells
Description: Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
Study NCT03546426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 3 MU s.c. from day +2 to day +6 after each DC administration
Study NCT00749684 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon α-2b
Description: 20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
Study NCT02796352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose bolus interleukin-2 (HD IL2)
Description: Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2.
Study NCT03665922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BroccoMax®
Description: Nutraceutical neoadjuvant
Study NCT03665922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study NCT04885179 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.
Study NCT04181983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized exercise program
Description: Home-based personalized exercise program using a smart phone app
Study NCT04181983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO exercise guidelines
Description: Standard exercise counselling according to WHO guidelines
Study NCT02235701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg/m2 aldoxorubicin
Description: administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study NCT01155037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
Study NCT01155037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
Study NCT01155037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
Study NCT01086566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
Study NCT04746651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Self Help
Description: Guided self help appointments with prison staff - 4x 30 minute appointments.
Study NCT01920503 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
Study NCT02224482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROGRESS
Description: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Study NCT03322774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment.
Study NCT01729234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate
Description: Dietary Supplement
Study NCT01729234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement
Study NCT04636606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Educational training program about oral dysphagia in patients with temporomandibular disorders.
Study NCT04636606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Combined with Home Exercise
Description: Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
Study NCT04636606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise
Description: Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
Study NCT02225977 — intervention group
Intervention type: DRUG
Intervention: Gilenya
Study NCT01918319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
Study NCT03863197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: Progressive Supervised Home-based Strength Training
Study NCT01988896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose as specified via IV infusion.
Study NCT01988896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
Study NCT00747123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
Study NCT00747123 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by the subcutaneous route of administration monthly for 4 doses.
Study NCT02475525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine enriched oral nutritional supplement
Description: oral nutritional supplement containing arginine
Study NCT03093740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Based on negative viral resistance testing of the donor treatment will be Zepatier
Study NCT03093740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier plus Sofosbuvir
Description: Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
Study NCT03322774 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: digital Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment.
Study NCT02400437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Study NCT02400437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Study NCT02400437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Doses given on Day 1 of induction and maintenance cycles.
Study NCT03949088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF and Na profiling
Description: Modulation of UF and dialysate sodium
Study NCT00994773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: daily doses for 14 days
Study NCT00994773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Study NCT00994773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir
Study NCT01508013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appearance-Focused Website Intervention
Description: The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
Study NCT01508013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Website
Description: The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
Study NCT00477477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
Study NCT00477477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
Study NCT03675074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neujia
Description: Neujia devices endoscopically deployed for jejunoileal compression anastomosis
Study NCT03939247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Tecaretherapy
Description: The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process
Study NCT03939247 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inactive Tecaretherapy
Description: Inactive Tecaretherapy: the device will not provide any current.
Study NCT03939247 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
Study NCT03939247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
Study NCT03939247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
Study NCT03428126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
Study NCT03428126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation.
Study NCT02172456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-radiolabelled tiotropium
Study NCT02172456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-radiolabelled tiotropium
Study NCT04324294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUS enhanced with contrast to evaluate pancreas
Description: Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
Study NCT04181840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and faeces tests
Description: During V1 - Laboratory tests, particularly for calprotectin concentration assessment
Study NCT04181840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy test
Description: During V1 - the electrical impedance of anal sphincter muscles will be measured
Study NCT04181840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Full gynecological and proctological examination
Description: During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
Study NCT04181840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transanal ultrasonography
Description: During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
Study NCT04181840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
Study NCT04181840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determining the degree of sphincter injury
Description: During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
Study NCT01805817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN® (Drospirenone/Ethinyl Estradiol)
Description: oral contraceptive pills
Study NCT01805817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Copper-T is an intrauterine device (IUD)
Description: intrauterine device for contraception
Study NCT01805817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing system
Description: intrauterine device
Study NCT00907517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion
Study NCT00733551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
Study NCT00733551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
Study NCT03322774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.